Recombinant Human Deoxyribonuclease 1 [EPC]

19633 reported adverse events

Drugs of this class: DORNASE ALFA

These side effects are most commonly reported by patients taking drugs of the Recombinant Human Deoxyribonuclease 1 [EPC] class:

# Side effect Count
0 INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS 2316
1 CYSTIC FIBROSIS 1776
2 HOSPITALISATION 1320
3 PNEUMONIA 1308
4 COUGH 1000
5 OFF LABEL USE 975
6 INFECTION 950
7 NO ADVERSE EVENT 944
8 DYSPNOEA 926
9 CONDITION AGGRAVATED 623
See all common reactions for Recombinant Human Deoxyribonuclease 1 [EPC]

Drugs of the Recombinant Human Deoxyribonuclease 1 [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 AMNIOTIC FLUID INDEX INCREASED 13 0.7222
1 INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS 2316 0.4251
2 CYSTIC FIBROSIS RESPIRATORY INFECTION SUPPRESSION 313 0.3505
3 CYSTIC FIBROSIS 1776 0.3205
4 CYSTIC FIBROSIS LUNG 36 0.2812
5 CYSTIC FIBROSIS RELATED DIABETES 32 0.2192
6 DISTAL INTESTINAL OBSTRUCTION SYNDROME 60 0.1780
7 BACTERIAL DISEASE CARRIER 89 0.1221
8 PULMONARY FUNCTION TEST DECREASED 494 0.1127
9 INFECTIVE EXACERBATION OF BRONCHIECTASIS 30 0.0977
See all enriched reactions for Recombinant Human Deoxyribonuclease 1 [EPC]